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OPEN
Review
The miR-17/92 cluster: a comprehensive update on its
genomics, genetics, functions and increasingly
important and numerous roles in health and disease
E Mogilyansky1 and I Rigoutsos*,1
The miR-17/92 cluster is among the best-studied microRNA clusters. Interest in the cluster and its members has been increasing
steadily and the number of publications has grown exponentially since its discovery with more than 1000 articles published in
2012 alone. Originally found to be involved in tumorigenesis, research work in recent years has uncovered unexpected roles for
its members in a wide variety of settings that include normal development, immune diseases, cardiovascular diseases,
neurodegenerative diseases and aging. In light of its ever-increasing importance and ever-widening regulatory roles, we review
here the latest body of knowledge on the cluster’s involvement in health and disease as well as provide a novel perspective on
the full spectrum of protein-coding and non-coding transcripts that are likely regulated by its members.
Cell Death and Differentiation (2013) 20, 1603–1614; doi:10.1038/cdd.2013.125
Facts
 MiR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-
92a-1 are members of the miR-17/92 cluster.
 The miR-17/92 cluster is important in cell cycle, prolifera-
tion, apoptosis and other pivotal processes.
 The miR-17/92 cluster is important in normal development
and also the first group of microRNAs (miRNAs) to be
implicated in a human syndrome (Feingold syndrome).
 The miR-17/92 cluster is also known as ‘oncomiR-1’.
 The miR-17/92 cluster is very often dysregylated in
hematopoietic and solid cancers.
 The miR-17/92 cluster is often dysregylated in cardiovas-
cular, immune and neurodegenerative diseases.
 The miR-17/92 cluster has been implicated in age-related
conditions.
 There are two models of miRNA targeting: the ‘standard’
that has been in use for a decade and the ‘expanded’
that is emerging with the help of recent technological
advances.
 The ‘standard’ model assumesWatson–Crick pairing in the
‘seed’ region of a miRNA and targets that are primarily in
the 30 untranslated region (30UTR) and conserved across
genomes.
 The ‘expanded’ model also incorporates Watson–Crick
pairing but additionally allows for combinations of
unmatched bases and G:U wobbles in the ‘seed’ region;
moreover, the targets can be anywhere along the messen-
ger RNA (not just the 30UTR) aswell as in the intergenic and
intronic genomic space; under this model, miRNA targets
need not be conserved.
Open Questions
 What currently unsuspected processes and human dis-
eases/conditions are regulated by the miR-17/92 cluster?
 Are there any protein-coding genes that are important for
human diseases or conditions and are regulated by the miR-
17/92 cluster?
 Does the miR-17/92 cluster have functionally significant
genomic targets in the intergenic and intronic parts of the
genome?
 Are there additional paralogues of the miR-17/92 cluster
that have not yet been reported?
 The presence of guanines and thymines in the seed region
of the cluster’s members suggests great potential for
targeting under the ‘expanded’ model; what is the relative
fraction of the cluster’s targets under the ‘expanded’ model?
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MiRNAs are abundant non-coding RNAs (ncRNAs), B22
nucleotides (nts) in length, which have significant roles in
regulating gene expression.1,2 The first animal miRNA, lin-4,
was discovered during a genetic screen in Caenorhabditis
elegans (C. elegans) and was found to repress the expression
of the protein-coding gene lin-14.3,4 In 2000, a secondmiRNA,
the well-conserved let-7, was discovered and functionally
characterized as important for C. elegans development.5
Since then, thousands of miRNAs have been predicted and
identified in animals, plants and viruses (see http://www.mir-
base.org).6–8
Herein, we focus on the miR-17/92 cluster of miRNAs and
review the current knowledge to date as to the roles of its
members in health and disease. In light of recent findings, we
also examine and discuss the topic of miRNA target
identification in the context of the miR-17/92 cluster.
The Cluster and its Paralogues
In 2004, a novel gene, ‘chromosome 13 open reading frame
25’ or C13orf25 for short, was identified.9 Analysis of 70
human B-cell lymphoma cases showed amplification of this
region.9 The miR-17/92 cluster as it is now known is located
in the locus of the non-protein-coding gene MIR17HG
(the miR-17/92 cluster host gene) (also known as C13orf25).
The miR-17/92 cluster transcript spans 800 nts10,11 out of
MIR17HG’s 7 kb and comprises six miRNAs: miR-17,
miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a-1
(Figure 1). The miR-17/92 cluster is conserved among
vertebrates.12 Soon after its discovery, the ectopic expression
of a truncated version of the cluster (lacking miR-92) in B-cell
lymphoma revealed its oncogenic character and miR-17/92
was given the distinction of being the first ‘oncomir’.13
The human genome contains two paralogues of the main
cluster (Figure 2): the miR-106b/25 and the miR-106a/363
cluster, respectively. MiR-106b/25 is located on chromosome
7 (7q22.1), in the 13th intron of the MCM7 gene. MiR-106a/
363 is located on chromosome X (Xq26.2). The miR-106b/25
cluster comprises three miRNAs: miR-106b, miR-93 and
miR-25 (Figure 2). The miR-106a/363 cluster comprises six
miRNAs:miR-106a,miR-18b,miR-20b, miR-19b-2, miR-92a-2
and miR-363. MiR-17/92 and miR-106b/25 are expressed
abundantly in a wide spectrum of tissues but miR-106a/363 is
expressed at lower levels.14,15 Together these three miRNA
clusters represent a combined total of 15 miRNAs that form
four ‘seed’ families: the miR-17 family, the miR-18 family, the
miR-19 family and the miR-92 family (Figure 3).
Transcriptional Regulation of the Cluster
One of the early findings was C-MYC’s involvement in
activatingMIR17HG transcription through a site that is located
1484 nts upstream of MIR17HG’s transcription start site.16,17
N-MYC also transcriptionally activates MIR17HG18 as well as
Figure 1 Genomic representation of the human miR-17-92 cluster host gene (MIR17HG) and neighborhood genes on Chr 13q31.1-q33-1. (a) Genomic representation of
genes located±10 kb around human MIR17HG. (b) Genomic representation of MIR17HG. Two transcripts are shown in light blue and individual members of the cluster
represented as red rectangles. The two panels were created using the UCSC genome browser (http://genome.ucsc.edu/)
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E2F1 and E2F3.19,20 The data show close functional interac-
tions between c-Myc/n-Myc and the miR-17/92 cluster. Both
c-Myc and n-Myc can directly bind to the promoter ofmiR-17/92
and initiate transcription.17,21,22 Indeed, some patients with an
N-MYCmutation have developmental abnormalities similar to
those in Feingold syndrome patients (see below).23,24
Additional information on transcriptional regulation became
available through the recent release by the ENCODE
(Encyclopedia of DNA Elements) project25 of data from the
study of 118 transcription factors (TFs). ENCODE’s results
revealed 1292 TF:miRNA interactions and 421 miRNA:TF
interactions that in turn suggest tightly coupled auto-regulatory
loops involvingmiRNAs and TFs. Of the 118 TFs, 34 pertain to
the miR-17/92 cluster: they include the previously known
MYC17,18 and MXI26,27 and 32 novel TFs (Figure 4). Among
the newly identified TFs, BCL3 was found to regulate miR-17/
92 and miR-106b/25. Further, BCL3, IRF1, SP1, TAL1 and
ZBTB33 are targeted by individual miRNAs of the cluster, in
addition to being TFs for the cluster (Figure 4). Moreover,
several novel targets for members of miR-17/92 and miR-
106b/25 were identified and are also summarized in
Figure 4.25,28 With regard to the miR-106a/363 cluster,
it is likely regulated by the microphthalmia-associated
transcription factor (MITF) through a binding site at position
133,135,780 (hg19) of chromosome X in the cluster’s
immediate vicinity.29
Among TFs, the E2F family (E2F1, E2F2 and E2F3) have a
central role in the regulation of G1 to S phase progression.30
All E2Fs,17,19 especially E2F3,20 have been shown to occupy
miR-17/92’s promoter region. E2Fs are also known to be
targeted by miR-17/92, forming an auto-regulatory loop
(Figure 4).19,20 Finally, recent studies indicate that TP53
targets the miR-17/92 cluster31 while also being targeted by
miR-25 through regulation of the latter by Myc and E2F1.32
Despite these significant advances, knowledge about the
transcriptional control of miR-17/92 and its paralogues
remains largely fragmentary. It is also important to note that
the specific processing of individual miRNAs adds a new level
of complexity; that is, it is conceivable that there is a cell-type-
dependent and context-dependent dimension to post-tran-
scriptional silencing.14,15,33,34
Main Targets of the miR-17/92 Cluster
Phosphatase and tensin homolog (PTEN) and E2Fs were
among the first validated miR-17/92 targets.15,17,19 Reporter
assays revealed targets for miR-19a and miR-19b-1 in
PTEN’s 30UTR, and the introduction of miR-19a and
miR-19b-1, or of the full cluster, in miR-17/92-deficient
cells sufficed to restore PTEN expression levels.15 In addition,
miR-17 and miR-20a modulate the expression of E2F1.17,19
Lastly, miR-20a targets the 30UTRs of both E2F2 and E2F3
(Figure 4).19
The ability of the cluster’s members to cooperate is evident
in the context of TGF-b signaling. In particular, miR-17 and
miR-20a directly target the TGF-b receptor II (TGFBRII),
whereas miR-18a targets Smad2 and Smad4, two members
of the TGF-b signaling pathway.35–37 TGF-b activation exerts
an effect mediated in part by the cyclin-dependent kinase
inhibitor (p21) and the apoptosis facilitator BCL2L11 (BIM),
both of which are targeted by miR-17/92.35,38 In addition,
BCL2L11 is targeted by miR-20a, miR-92, miR-19a and
miR-19b-115 and also by miR-106b/25.39 During the
endoplasmic reticulum related stress, unfolded protein
response TFs, activating TFs, activating transcription factor
4 (Atf4) and nuclear factor-erythroid-2-related factor 2 (Nrf2)
are activated and downregulate Mcm7, the host gene for the
miR-106a/25 cluster. Downregulation of miR-106b/25 and
repression of BCL2L11 consequently trigger apoptosis.39
Lastly, miR-18a and miR-19 directly repress the anti-
angiogenic factors thrombospondin-1 (TSP-1) and connective
miR-17 miR-18a miR-19a miR-20a miR-19b-1 miR-92a-1miR-17/92Chr 13q31.3
miR-19b-2 miR-92a-2miR-106a miR-18b miR-20b miR-363miR-106a/363Chr Xq26.2 
miR-106b miR-93 miR-25miR-106b/25Chr 7q22/1 
Figure 2 Members of the miR-17/92 cluster and its two paralogues miR-106a/363 and miR-106b/25 and their chromosomal location. Red: members of the miR-17 family;
blue: members of the miR-18 family; green: members of the miR-19 family; orange: members of the miR-92 family
miR-17 family
miR-18 family
miR-92 family
miR-19 family
Figure 3 Sequences of the members of the miR-17/92 cluster (in bold face) and
its two paralogues miR-106a/363 and miR-106b/25. The sequences are divided into
four families according to the miRNA ‘seed’ (the sequence spanning positions 2
through 7 inclusive counting from the 50 end of the miRNA). The ‘seed’ in each case
is shown in boldface and is highlighted in blue
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tissue growth factor (CTGF).40 In addition, miR-17 and miR-20a
participate in the regulation of the insulin gene enhancer
protein (Isl-1) and the T-box 1 protein (Tbx1) (Figure 4).41
MiR-17/92 and Normal Development
The miR-17/92 cluster is highly expressed in embryonic
cells15 and has an important role in development.
MiR-17/92 was the first group of miRNAs to be implicated in
a developmental syndrome in humans. Indeed, studies of
patients with Feingold syndrome revealed an important role
for the miR-17/92 cluster in normal skeletal development.24
Human patients with heterozygous microdeletions in the
MIR17HG locus have autosomal dominant Feingold syn-
drome, characterized by multiple skeletal abnormalities in the
fingers and toes, short stature and microcephaly. Some
patients also show various degrees of learning and develop-
mental disabilities.24
Subsequent mouse studies showed that deletion of the
miR-17/92 cluster is perinatal lethal.15 MiR-17/92 /
embryos exhibit severe skeletal abnormalities and recapitu-
late the phenotype observed in patients with Feingold
syndrome. The mice are also smaller in size than normal
embryos, and die at birth from cardiac defects and lung
hypoplasia.15,22 The miR-17/92 cluster is involved also in
normal lung morphogenesis, epithelial proliferation and
branching through the targeting of signal transducer and
activator of transcription 3 (STAT3) and mitogen-activated
protein kinase 14 (MAPK14).42 The overexpression of the
miR-17/92 cluster leads to lung epithelium hyper-proliferation
and suggests a role in lung cancer.43
Analogously to themiR-17/92 studies that indicated a role in
B-cell differentiation, the normal process of B-cell maturation
in miR-17/92-/-mice is blocked during the progression from
pro-B to pre-B cells. Mice with a deleted miR-17/92
cluster have a reduced number of pre-B cells at E18.5.15
In experiments with adult mice whose hematopoietic system
is reconstituted with fetal liver cells from a miR-17/92Dneo/Dneo
embryo at E14.5, the number of circulating lymphocytes,
circulating B cells, splenic B cells and pre-B-cells bone
marrow cells is significantly reduced compared with mice with
reconstituted fetal liver cells from wild-type embryos at 8–10
weeks post transplant.15 Mice that were irradiated and had
their hematopoietic system reconstituted with hematopoietic
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stem cells (HSC) derived from fetal liver of Em-myc transgenic
mice expressing miR-17/19 under the control of murine stem
cell virus (MSCV) show a massive enlargement of lymph
nodes, splenic hyperplasia, infiltration of the thymus by
lymphoma cells and leukemias.13 Moreover, almost half of
the animals in the test group exhibited hind leg paralysis as the
result of tumors at the lumbar node. These results suggest the
importance of miR-17/92 in normal B-cell development and
survival. On the other hand, overexpression of the cluster was
also shown to cause lymphoproliferative diseases.44
Parallel studies have also implicated miR-17/92 in normal
lymphocyte development.45 In mouse knockout models, miR-
19b-1 and miR-17 were shown to promote T-cell expansion;
the mice display reduced lymphocyte proliferation that was
attributed to the promotion of interferon-g (IFNg) production by
miR-19b-1 and the promotion of a Th1 response by miR-17
and miR-19b-1.45 Indeed, miR-17 and miR-19b-1 have an
important role in promoting B-cell proliferation, protecting
B-cells from death, supporting IFNg production and suppres-
sing T-cell differentiation.45
The Cluster as an Oncogene
We next review the increasing body of literature on the
cluster’s oncogenic role (Table 1).46,47
B-cell Lymphomas
The miR-17/92 cluster was initially found amplified in diffuse
cell lymphomas.9 Later, in B-cell lymphoma, an ectopically
overexpressed truncated version that lacked miR-92 showed
the cluster’s role as an oncogene.13 Moreover, as already
discussed, c-Myc was shown to transcribe the truncated
cluster in mousemodels of B-cell lymphoma.13 These findings
represent early evidence that miR-17/92 can act as an
oncogene by suppressing apoptosis.13 MiR-18a levels in
diffuse large B-cell lymphoma correlate strongly and nega-
tively with survival (higher expression-shorter survival).48
Asmentioned already,miR-19a andmiR-19b-1 are necessary
and sufficient to promote tumorigenesis B-cell lymphoma.49–51
In addition, the conditional knockout of miR-17/92 in Myc-
driven lymphomas was shown to increase apoptosis and to
reduce tumorigenicity and tumor progression.49
B-cell Chronic Lymphocytic Leukemia
MiR-20a was found to correlate with diagnosis to treatment
time in B-cell chronic lymphocytic leukemia (CLL) and thus
can potentially serve as a blood biomarker.52 The cluster
members miR-17 and miR-19b-1 are highly overexpressed in
CLL cultures with fibroblast expressing human CD40 ligand
(CD154) with IL-4. Another study foundmiR-20, miR-18a, miR-
Table 1 Relative expression of individual miRNAs from the miR-17/92 cluster or its paralogues in normal development, cancer, other diseases and age-related
conditions
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19a and miR-92a to be overexpressed in CLL cultures, but at
much lower levels than those of miR-17 and miR-19b-1.53
Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a heterogeneous group of
diseases with different genetic rearrangements, different
prognosis and required treatment options. MiR-17-5p, miR-
17-3p, miR-20a and miR-92 are upregulated in myeloid/
lymphoid, or mixed-lineage leukemia (MLL), display rearran-
gements in AML and are downregulated in AML with the
translocation t(8;21). On the other hand,miR-17-5p andmiR-20a
are downregulated in t(15;17). AMLwithMLL-rearrangements
is considered to have intermediate or poor prognosis;
moreover, it requires a different treatment from AML with
t(8;21)/t(15;17) that usually carries a favorable prognosis.54 In
mouse studies, the levels of miR-106 were found to
be upregulated in AML and to target Sequestosome 1
(SQSTM1).55 In AML characterized by the translocation
t(8;16)(p11;p13), miR-17/92 is downregulated.56 However,
there is no significant difference in the expression of MYC
between t(8;16)(p11;p13) AML and other types of AML
suggesting that other mechanisms of downregulation, for
example, methylation, may be at work.56
T-cell Lymphoma
In an experiment with the SL3-3 murine leukemia virus, 2545
BALB/c newborn mice were infected and nearly all developed
T-cell lymphoma. Quantitative RT-PCR analysis showed
elevated expression of miR-17/92 after virus integration.57
ThemiR-17/92 integration sites were found to cluster together
at three distinct regions; the integration sites within each such
region wereB1 kb apart.57
Retinoblastoma
Overexpression and genomic amplification of miR-17/92 were
shown in retinoblastoma.58 In particular, in Rb / and
p107 / retinoblastomas, ectopic expression of miR-17/92
induces rapid proliferation and disease onset. This increase in
proliferation is linked to the miR-17 sub-family, which target
the cell cycle inhibitors p21Cip1 and p57Kip2.58,59
Colorectal Cancer
MiR-17/92 was also found overexpressed in colon cancer.40
In a tumor engraftment model, upregulation of the cluster by
Myc in colonocytes increased tumorigenesis by promoting
angiogenesis through direct repression of TSP-1 and CTGF
by miR-18a and miR-19, respectively.40 MiR-18a and miR-
20a are significantly overexpressed in colorectal cancer
(CRC); in fact, miR-18a is a marker of poor prognosis.60
In addition, miR-92 levels in colon adenocarcinoma have been
shown to correlate negatively with BCL2L11 expression and,
thus, with reduced apoptosis.61 High miR-17 expression
correlates with low overall survival in patients with CRC.62
Another study that comprised 90 patientswithCRC, 90 patients
with inflammatory bowel diseases (IBD), 20 patients with
gastric cancer and 50 healthy controls also confirmed high
expression level of miR-17 and miR-92 in tumors and serum
from patients with CRC.63 Patients with CRC had higher miR-
92 levels compared with healthy controls or patientswith IBD or
gastric cancer.63 Interestingly, results revealed a correlation
between miR-18a expression and Adenomatous Polyposis
Coli (APC) mutation in CRC samples.64
Head and Neck Cancers
MiR-17/92 is often overexpressed in meduloblastomas,
especially those with an active Sonic hedgehog signaling
pathway. The cluster is overexpressed in mouse models in
cerebellar granule neuron progenitors, where the tumor
arises.65,66 Ectopic expression of miR-17/92 increases
tumor formation through the suppression of TGF-b signaling
upon orthotopic transplantation into immunocompromised
mice.65,66 These studies suggest a tissue-specific function for
members of the miR-17/92 cluster. The miR-17/92 cluster
amplification was also reported in neuroblastomas and is
linked to poor prognosis.67 Lastly, miR-17 has been shown to
promote the growth of neuroblastoma cell lines.68
Pancreatic Cancer
In pancreatic cancer, miR-17, miR-18a, miR-19a and miR-
19b-1 expression levels are increased.69,70 Another study
also showed that the level of miR-18a in the blood is
significantly higher before surgery in patients with pancreatic
cancer compared with after surgery, suggesting the possibility
that blood levels of miR-18 can potentially be used as a
biomarker.70
Breast Cancer
Deep sequencing of triple negative breast cancer (TNBC)
samples revealed a threefold increase of miR-17/92 levels.71
In estrogen receptor (ER)-positive breast cancer, it was
shown that miR-18a/-18b directly target the 30UTR of the
ERa.72 In addition, miR-17 and miR-20 are overexpressed in
metastatic breast cancer73 and have been shown to directly
suppress the 30UTR of IL-8 and to inhibit cytokeratin 8 through
cyclin D1.73 Another study has shown that miR-106b
positively correlates with homeotic TF Six1 expression levels
in breast cancer:74 Six1 depends on the upregulation of the
TGF-b pathway to induce epithelial–mesenchymal transition.
In addition, high levels of miR-106b are indicative of shorter
time to relapse.74
Ovarian Cancer
Studies have implicated the overexpression of miR-20a in
proliferation and invasion in the OVCAR3 cell line, whereas
the downregulation of miR-20a has been shown to lead to
the suppression of proliferation and invasion. A possible
mechanism is through binding to the amyloid protein
precursor (APP), a gene of central importance in Alzheimer’s
disease (AD).75
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Lung Cancer
In lung cancer, miR-17-5p and miR-20a are overexpressed.76
Their targets include HIF-1a, PTEN, BCL2L11, CDKNA and
TSP-1.76 A study of 221 lung cancer patients and 54matching
controls showed a significant increase of miR-17-5p expres-
sion in tumor and serum and a negative correlation with
patient survival.77 However, the blood of non-small cell lung
cancer patients had a low level of miR-17-5p.78
Renal Cancer
The miR-17/92 cluster is regulated by the von Hippel-Lindau
(VHL) tumor suppressor: in the absence of VHL, miR-17/92
levels increase.79 Other studies have shownmiR-17, miR-18a
and miR-20a to be overexpressed in renal cancer; however,
overexpression of these miRNAs did not correlate with
survival.80,81
Hepatocellular Carcinoma
All six members of the miR-17/92 cluster are often over-
expressed in hepatocellular carcinoma (HC).82 The use of
antisense nts specific to all six members of the miR-17/92
cluster caused a 50% reduction in proliferation and anchorage-
independent growth.82 In addition, severalmembers ofmiR-17/92
and its paralogues (miR-92,83 miR-18a, miR-106b, miR-93
andmiR-2584) are highly expressed in HC cells comparedwith
paired non-tumor samples. Another study showed that miR-18,
and the miR-106b/25 paralogue, was overexpressed in 50%
of clinical samples used in the study.84 Cell culture studies
have also shown that the knockdown of miR-106b/25 leads to
decreased cell proliferation and anchorage-independent
growth in three different cell lines: HepG2, HeLa and HuH7.84
Osteosarcoma
MiR-17/92 is overexpressed in osteosarcoma as demon-
strated by luciferase assays.85 In particular, miR-17 andmiR-20a
are overexpressed in metastasized cells compared with
parental cells.86 In addition, mouse studies with anti-miR-20a
showed significant increase in lung metastases, possibly
through the repression of FasL in the lung tissues.86
The Cluster in Other Diseases
Beyond cancer, themiR-17/92 cluster has been shown to have
important roles in other human conditions including immune,
cardiovascular and neurodegenerative diseases.87–90
Immune Diseases
The miR-17/92 cluster has a role in the innate and acquired
immune response.88 In human cord blood, CD34þ hemato-
poietic progenitor cells differentiate into monocytes upon
exposure to macrophage-colony stimulating factor (M-CSF)
and the miR-17/92 cluster.91 MiR-17/92 also has a role in the
acquired immune response.88 Another study has shown that
autoimmunity, characterized by increased proliferation and
survival of CD4þ T cell, could be caused by overexpression
of the miR-17/92 cluster in the DN1 stage.88
Cardiovascular Diseases
MiR-92a is highly expressed in endothelial cells but over-
expression of miR-92a in those cells under ischemic condi-
tions was shown to inhibit angiogenesis.92 In a mouse model
with leg ischemia, the administration of antagomiR-92a led to
inhibition of miR-92a with consequent growth of new blood
vessels and recovery from ischemia.92 In another study,
endothelial cells from patients with coronary artery disease
(CAD) exhibited higher levels of miR-17 and miR-92a
compared with endothelial cells from healthy controls.93,94
In another study, the miRNA profile of patients with acute
coronary syndrome showed an increase of miR-19 compared
with patients with CAD.95 And a study of miRNA levels
measured by quantitative RT-PCR in whole blood and serum
showed reduced miR-19a levels in patients with CAD
compared with healthy controls.
Neurodegenerative Diseases
The amyloid precursor protein APP generates the amyloid-b,
Ab, peptide through the ‘amyloidogenic’ pathway with the help
of b- and g-secretases. Ab accumulates in extracellular
spaces forming Ab plaques. Members of the miR-17 family
(i.e., miR-17, miR-20a, miR-106a and miR-106b) were shown
to directly suppress APP in vitro.96,97 In the AD brain, miR-
106b was shown to be downregulated in vivo.97
In relapsing patients with multiple sclerosis (MS), miR-18
was found to be overexpressed compared with controls.98
Another study of CD4þ T cells and B cells of relapsing and
remitting MS patients shows the upregulation of miR-17-5p in
CD4þ T cells and downregulation of miR-92 in B cells.99
Another study has shown under-expression of miR-17 and
miR-20a in whole-blood samples from 59 MS patients
compared with 37 healthy controls.100 The MS patients
represented different disease types (primary progressive,
secondary progressive and remitting-relapsing) and for the
last 3 months before the study had not received any
treatment. In addition, miR-106b and miR-25 were found to
be upregulated in 12 relapsing-remitting MS patients and in 14
healthy controls.101 A recent analysis used an integrative
approach to study miRNAs dysregulated in MS revealed that
miR-20a and miR-20b targetB500 genes each.102
On a related note, profiling of miRNA expression in the brain
of zebrafish (Danio rerio) showed that miR-92 is expressed in
periventricular cells and in proliferative zones of larva and
adult brain and down-regulated in mature neurons.103
The Cluster and Age-Related Conditions
Considering the importance of miR-17/92 in tumorigenesis,
it was not long before the relation between dysregulation
of these miRNAs and aging was discovered.104,105 Studies
of different tissue types representing aging revealed down-
regulation of miR-17, miR-19b, miR-20a and miR-106a.106
This suggests yet another role for these miRNAs, one that
transcends cell cycle regulation and tumorigenesis. However,
the mechanistic connection between downregulation of the
cluster’s members and aging has yet to be elucidated.105
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The Potentially Wide Spectrum of Coding and
Non-coding Sequences Targeted by the Cluster
It should be clear by now that the cluster’s members are
involved in very diverse settings and a wide range of post-
transcriptional regulatory events. The experimental findings to
date about the cluster’s targetome have been driven primarily
by the analyses of gene-expression array data. The exact
mechanistic aspects of those interactions have been eluci-
dated in only relatively few contexts. To better appreciate the
range of possibilities and to place the cluster’s known (and
unknown) targets in the appropriate light, it is important to first
review briefly how miRNA target prediction has been
practiced.
A miRNA effects the post-transcriptional regulation of its
targets in a sequence-dependent manner. The ‘seed’ in
particular, that is, the sequence spanning positions 2–7
inclusive from the 50 end of a miRNA, is especially important
for target determination and coupling.1,5,107–113 Early genetic
studies and subsequent efforts demonstrated that miRNAs
can function in the presence of inexact matches and/or bulges
in the seed region.108,109,111,114–125 Despite the potential
diversity of targets, there has been a strong adherence
throughout to a ‘standard’ model that anticipates exact base-
pairing, that is, Watson–Crick, and the absence of any bulges
in the seed region. Consequently, the majority of the designed
algorithms treated these criteria as necessary and sufficient
attributes of bona fide targets and combined them with the
enforcement of cross-genome conservation. However, algo-
rithms were also proposed that neither enforced nor used
these constraints, for example, rna22.126 As a matter of fact,
rna22 permits Watson–Crick and G:U pairs in the seed region
as well as bulges; moreover, a candidate target does not have
to be conserved across organisms and can be located
anywhere.
An additional element, likely guided by the early
C. elegans studies with the 30UTR of the lin-14 and lin-41
genes, relates to an adherence to seek miRNA targets
primarily in the 30UTR of the candidate mRNAs. Never-
theless, the use of artificial constructs demonstrated the
absence of any mechanistic constraints that would prevent
the targeting of other mRNA regions by miRNAs: let-7 target
sites embedded in the coding sequence (CDS) were shown
to be functional.127 Analogously, the introduction of miRNA
target sites into the 50UTR of luciferase reporter mRNAs
containing internal ribosome entry sites (IRESs) revealed
that miRNAs could regulate the abundance of a target by
binding to its 50UTR.128
Further support for these findings came more recently
through a number of efforts by our group and others that
reported the discovery and validation of extensive and
naturally occurring miRNA targets in the CDS of an mRNA
as well as its 50UTR.129–134 In earlier work, we estimated that
as many as 90% of the known protein-coding human genes
could be targeted by miRNAs.126 On a related note, miRNAs
were recently shown to also target intergenic and intronic
regions, pseudogenes and long ncRNAs.119,121,123,135,136
Another dimension of the miRNA target prediction
problem relates to the observation of conservation of miRNA
sequences across animals and plants (and viruses). At the
sequence level, most miRNAs are evolutionarily conserved
among distant species.137 However, not every known
miRNA is conserved: indeed, there are reports of miRNAs
that are species- or genus-specific.138,139 Moreover, it is
known that conserved miRNAs do not have the same
functional behavior in different species: let-7, which is
conserved between C. elegans and Drosophila melanogaster,
is a characteristic example. In the worm, let-7 is a component
of the heterochronic pathway; it is expressed at a late stage of
larva development, regulates the transition from larva to adult5
and is embryonic lethal.140 In the fruit fly, let-7-knockout flies
are externally normal but exhibit behavioral defects and
juvenile features in their neuromusculature.141
In recent work113 we used molecular dynamics to analyze
the crystal structure of the Argonaute (Ago) silencing complex
and demonstrated in a very general way the existence of
many admissible targets that transcend the ‘standard’ model
that has been in use for more than a decade already. The
molecular dynamics findings were further corroborated by
publicly available Ago-immunoprecipitated119 and sequenced
miRNA targets.113 These results provide strong evidence in
support of an expanded model of miRNA targeting and are
very relevant for the members of themiR-17/92 cluster and for
our estimates of this cluster’s targetome (Figure 5). Glimpses
of evidence supporting the ‘expanded’ model were also
observed experimentally in earlier work109,111,116–118 as well
as discussed in the literature.110,112,124,130,142
The members of miR-17/92 clusters are ideal miRNAs for
which to explore ‘unexpected targets’ under the ‘expanded’
model. Indeed, as all of the members have at least two G/U
bases in their seed region, (Figure 3) they could potentially
base pair with U and G, respectively, on the side of the target
to create wobbles and additional targets (Figure 5).
In addition, potential incorporation of bulges on either the
miRNA or the target side would lead to an even higher number
of non-standard targets.
There is also increasing evidence with regard to non-
protein-coding transcripts that could be targeted by miRNAs.
The evidence comes both from studies of individual
miRNA:target pairs as well as global analyses. In particular,
it has already been shown for several miRNAs, some
belonging to the miR-17/92 cluster, that they target
and suppress the expression of PTENP1, the PTEN
pseudogene.143,144 The same study also showed targeting
and regulation by miRNAs of the KRAS pseudogene
KRASP1 as well as of several of the pseudogenes of
OCT4. More recently,136 it was shown that miR-133 andmiR-
135 target a long non-coding RNA, linc-MD1, thereby
regulating the expression of MAML1 and MEF2C, two TFs
that activate muscle-specific gene expression. In addition,
the advent of the crosslinking and immunoprecipitation
followed by high-throughput sequencing (CLIP-seq) tech-
nology has enabled global studies of miRNA targeting
preferences in a variety of contexts.119,123,145–147 Initial
analyses of the available data have provided additional
evidence that miRNA-targeted transcripts include numerous
transcripts that are not protein-coding.113
These findings indicate that the miR-17/92 targetome may
be larger and further ranging than originally anticipated. As we
saw above, several members of the miR-17/92 cluster have
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been implicated in the regulation of non-protein-coding
transcripts. In addition, the sequence composition of the seed
region of the cluster’s members and in particular the presence
of G/U’s in the seed provides them with an expanded base-
pairing ability. Consequently, there is great potential that a
very rich set of currently unrecognized heteroduplexes
comprising miRNAs of the miR-17/92 cluster awaits
discovery.
Conclusion
MiR-17/92 is one of the best-known miRNA clusters. The
cluster’s members have pivotal roles in normal development,
and dysregulation of their expression leads to a wide array of
diseases including hematopoietic and solid cancers, and
immune, neurodegenerative and cardiovascular diseases.
The cluster is also important because its members are the first
described in the context of a developmental syndrome in
humans. Related to this, other recent work uncovered novel
important connections between the miR-17/92 cluster and
aging.
Despite great progress in understanding the cluster’s roles,
several key questions remain unanswered. For example, until
the recently reported findings by the ENCODE project very
little was known about the transcriptional control of the cluster
by TFs as well as about the targeting of TFs by members of
the cluster and its paralogues. Considering the ENCODE
project’s findings, it is reasonable to conjecture that the actual
transcription control of the cluster is significantly more
complex than research to date has managed to reveal.
A parallel and very important question is that of elucidating
the cluster’s targetome. The currently known set of validated
protein-coding targets is small. In light of the many miRNAs
that the cluster and its paralogues comprise and the recent
evidence obtained through molecular dynamics studies and
CLIP-seq data analyses, it is increasingly apparent that the
true spectrum of targets is potentially very large. Additional
research effort will be needed before the full complement of
the cluster’s targets can be elucidated. It is also important to
note that an increased target set opens up new opportunities
and new avenues for therapeutic intervention in those
settings, where one or more of the cluster’s members are
dysregulated.
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Figure 5 Differences between the ‘standard’ and ‘expanded’ model of miRNA targeting and the corresponding targetome. The seed of miR-18 is used as an example
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